Biotin for Progressive MS: Surprise from the American Academy of Neurology Meeting

June 6, 2015 Pavle Repovic, MD, PhD

Undoubtedly the most talked-about study presented at the annual meeting of the American Academy of Neurology in Washington, DC, was the study of high-dose biotin for progressive MS (PPMS or SPMS). The authors conducted a randomized, double-blinded, placebo-controlled study across 16 MS centers in France, comparing placebo with MD1003, a proprietary purified high dose biotin. 154 patients participated in this 12-month study. The primary endpoint of the study was the proportion of patients who improved at 9 months (compared to the entry at the study), with sustained improvement at 12 months. 12.6% of patients in the MD1003 arm improved, compared to 0% in the placebo arm. The treated group, as a whole, had improved disability scores compared to placebo group. MD1003 was well-tolerated.

Although short, these results offer a tantalizing possibility of treatment for progressive MS. The findings will need to be replicated in a larger, possibly longer study. Stay tuned for the news of when/where that study may take place; but bear in mind that more than likely it will involve a placebo arm. 

Previous Article
Mark's perspective on Ethiopia

Mark, my husband, has a different perspective regarding our stay in Ethiopia. He was interviewed by his com...

Next Article
Neuroplasticity Model of Music Therapy

Listen to this podcast about how music therapy can help stimulate alternative pathways in the brain as well...